Pfizer Touts Prevnar 13 Superiority As Initial Vaccine In Older Persons Before ACIP
Pfizer got to present a dry run of its case for Prevnar 13 as a superior initial vaccine for adults 50 and older to the Centers for Disease Control’s Advisory Committee on Immunization Practices Oct. 26.
You may also be interested in...
New post-marketing commitment will look at conjugate pneumonia vaccine when given in patients 50 and older who have already received Merck’s polysaccharide vaccine.
Advisory committee votes 14-1 in favor of effectiveness and safety in adults 50 and older.
The world's largest pharma highlights sales growth of Prevnar 13, Enbrel and Lyrica, emerging markets growth, and a developing plan to sell off animal health and nutritional units.